Fig 1.
Flow diagram for patient selection.
The Surveillance Epidemiology and End Results (SEER) 1990–2013 database was used to identify patients diagnosed with breast carcinoma. Patients were excluded if their disease was not malignant or the age was unknown. And other histology types of disease, including mixed disease were excluded. As the result, the patients were divided into two groups, infiltrating ductal carcinoma (IDC) and infiltrating lobular carcinoma (ILC).
Table 1.
Baseline demographic and clinicopathologic characteristics of the 796,335 study patients.
Fig 2.
Comparison of overall survival (OS) rates and disease-specific survival (DSS) rates of infiltrating ductal carcinoma (IDC) and infiltrating lobular carcinoma (ILC).
Table 2.
Multivariable cox proportional hazards analysis of clinicopathologic factors associated with survival, stratified by histology types.
Fig 3.
Comparison of overall survival (OS) rates and disease-specific survival (DSS) ratesof infiltrating ductal carcinoma (IDC) and infiltrating lobular carcinoma (ILC) based on hormone receptor status.
Table 3.
OS and DSS comparison in different hormone receptor status of ILC and IDC.
Fig 4.
Kaplan–Meier survival curves of infiltrating ductal carcinoma (IDC) and infiltrating lobular carcinoma (ILC) based on hormone receptor statusmatched by stage.
OS, overall survival; DSS, Disease-specific survival.
Table 4.
Comparison of infiltrating ductal and infiltratinglobular histological types according to the metastasis sites and counts.
Fig 5.
Comparison of overall survival (OS) rates and disease-specific survival (DSS) rates of infiltrating ductal carcinoma (IDC) and infiltrating lobular carcinoma (ILC) stratified by different metasasis sites.